PROTECT-PROCOSE (ACARBOSE TABLETS)--DIABETES

PROTECT-PROCSE（阿卡波糖片）--糖尿病

• 批准号: 6245048
• 负责人: John Bernard Buse
• 金额: $ 1.34万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-06 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245048
• 关键词: alpha glucosidase; carbohydrate metabolism; clinical research; combination therapy; diabetes mellitus therapy; diet therapy; dosage; drug adverse effect; drug screening /evaluation; exercise; human subject; human therapy evaluation; noninsulin dependent diabetes mellitus; sulfonylurea

Acarbose is an competitive inhibitor of intestinal brush border alpha- glucosisdases. it results in a slowing of carbohydrate absorption and has been approved by the FDA for treatment of non-insulin dependent diabetes mellitus in conjunction with diet and exercise or with sulfonylureas. The drug is targeted for a national distribution on or around 12/15/95. The study is designed to determine if starting dosing titration schemes at a lower dose and going up slowly will result in fewer side effects.

Acarbose是肠道边界α-的竞争性抑制剂 糖酶酶。 它导致碳水化合物的吸收减慢和 FDA已批准用于治疗非胰岛素依赖性 糖尿病与饮食和运动结合或与 磺酰脲。 该药物针对的是在或 大约12/15/95。 该研究旨在确定是否开始给药 较低剂量的滴定计划将导致 较少的副作用。